Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
43 Results for "
neuroendocrine tumor
" in MedChemExpress (MCE) Product Catalog:
Products (43)
43 Results for "neuroendocrine tumor" in MCE Product Catalog:
13
13 Publications Verification
Synonyms: DCC-2036
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1 WT and Abl1 T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia .
4
4 Cited Publications
Cat. No.: HY-W008253
CAS No.: 54-16-0
Category:
Immune System Disorder Monophenols Ketones, Aldehydes, Acids Disease markers Endocrine diseases Phenols Nervous System Disorder Endogenous metabolite Cancer
Target:
4
Target:
Research Areas:
(Z)-Semaxanib ((Z)-SU5416) is a VEGF receptor tyrosine kinase inhibitor that blocks VEGF signaling through Flk-1/KDR. (Z)-Semaxanib inhibits angiogenesis by preventing new blood vessel formation. (Z)-Semaxanib induces cytotoxicity in liver cancer cells. (Z)-Semaxanib can be used in research on metastatic renal cell carcinoma, gastrointestinal stromal tumors, well-differentiated pancreatic neuroendocrine tumors, and solid tumors .
2
2 Cited Publications
Synonyms: DOTATOC; SDZ-SMT 487; SMT 487
Research Areas:
2
2 Cited Publications
Cat. No.: HY-P10102
CAS No.: 629628-53-1
2
Target:
1
Research Areas:
1
Target:
Research Areas:
m-Iodobenzylguanidine (Iobenguane) is a ligand with high affinity against norepinephrine transporter (NET). m-Iodobenzylguanidine is used as an imaging agent in the diagnostic imaging and radionuclide studies of neuroendocrine tumors, such as neuroblastoma, pheochromocytoma and carcinoid tumor .
Research Areas:
MRT-2359 is an orally active and selective GSPT1 molecular glue degrader, with a DC50 of 5 nM. MRT-2359 induces CRBN/GSPT1 ternary complex formation to drive CRBN- and degron-dependent proteasomal GSPT1 degradation, with selectivity for wild-type GSPT1 over the GSPT1G575N mutant. MRT-2359 disrupts protein translation, induces ribosome stalling, downregulates MYC family proteins and their transcriptional output, reduces proliferation, and induces apoptosis in cancer cells. MRT-2359 can be used for the research of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), neuroendocrine lung cancer, high grade neuroendocrine cancers, diffuse large B-cell lymphoma, prostate cancer, and MYC-driven solid tumors .
Cat. No.: HY-P9978
CAS No.: 1924598-82-2
Synonyms: JS-001; TAB-001; Tripleitriumab; CHS-007; Teriprizumab; Treprizumab
Target:
Research Areas:
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
Cat. No.: HY-173158
CAS No.: 3031593-79-7
Target:
Research Areas:
AUR1545 is a selective KAT2A/KAT2B ((GCN5/PCAF)) PROTAC degrader that induces monocyte differentiation and inhibits the growth of acute myeloid leukemia cells. AUR1545 inhibits cell growth, induces epithelial differentiation and suppresses tumor growth in small cell lung cancer models. AUR1545 inhibits cell growth and induces differentiation in neuroendocrine prostate cancer cells and primary patient-derived organoids. AUR1545 is applicable to research related to acute myeloid leukemia, small cell lung cancer and neuroendocrine prostate cancer .
Cat. No.: HY-170554
Cat. No.: HY-164729
Cat. No.: HY-P10920
CAS No.: 2415661-92-4
Target:
Research Areas:
Cat. No.: HY-P991731
Synonyms: ZG006
Research Areas:
Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .
Cat. No.: HY-P5362
Research Areas:
Cat. No.: HY-W008253S2
CAS No.: 81587-11-3
Research Areas:
PRX-08066 is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 inhibits pulmonary vascular remodeling. PRX-08066 can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET) .
Cat. No.: HY-W008253S1
Cat. No.: HY-W008253R
CAS No.: 54-16-0
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
